Advertisement
NVAX or PRTA or REGN
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVAX’s FA Score shows that 1 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s), and REGN’s FA Score reflects 1 green FA rating(s).
- NVAX’s FA Score: 1 green, 4 red.
- PRTA’s FA Score: 0 green, 5 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVAX’s TA Score shows that 6 TA indicator(s) are bullish while PRTA’s TA Score has 4 bullish TA indicator(s), and REGN’s TA Score reflects 6 bullish TA indicator(s).
- NVAX’s TA Score: 6 bullish, 4 bearish.
- PRTA’s TA Score: 4 bullish, 4 bearish.
- REGN’s TA Score: 6 bullish, 4 bearish.
Price Growth
NVAX (@Biotechnology) experienced а +14.46% price change this week, while PRTA (@Biotechnology) price change was +7.28% , and REGN (@Biotechnology) price fluctuated +3.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.
Reported Earning Dates
NVAX is expected to report earnings on Nov 05, 2025.
PRTA is expected to report earnings on Oct 30, 2025.
REGN is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Biotechnology (+9.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NVAX | PRTA | REGN | |
| Capitalization | 1.56B | 444M | 61.5B |
| EBITDA | 555M | -137.71M | 5.42B |
| Gain YTD | 19.154 | -40.433 | -18.294 |
| P/E Ratio | 4.32 | N/A | 14.63 |
| Revenue | 1.22B | 138M | 14.2B |
| Total Cash | 731M | 418M | 7.47B |
| Total Debt | 229M | 10.2M | 2.71B |
NVAX | PRTA | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 76 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 57 Fair valued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 95 | 54 | |
PRICE GROWTH RATING 1..100 | 40 | 56 | 63 | |
P/E GROWTH RATING 1..100 | 10 | 94 | 95 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 48 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for PRTA (57) and is significantly better than the same rating for NVAX (84). This means that REGN's stock grew somewhat faster than PRTA’s and significantly faster than NVAX’s over the last 12 months.
REGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRTA (100) and is in the same range as NVAX (100). This means that REGN's stock grew similarly to PRTA’s and similarly to NVAX’s over the last 12 months.
REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for PRTA (95) and is somewhat better than the same rating for NVAX (100). This means that REGN's stock grew somewhat faster than PRTA’s and somewhat faster than NVAX’s over the last 12 months.
NVAX's Price Growth Rating (40) in the Biotechnology industry is in the same range as PRTA (56) and is in the same range as REGN (63). This means that NVAX's stock grew similarly to PRTA’s and similarly to REGN’s over the last 12 months.
NVAX's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for PRTA (94) and is significantly better than the same rating for REGN (95). This means that NVAX's stock grew significantly faster than PRTA’s and significantly faster than REGN’s over the last 12 months.
| NVAX | PRTA | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 85% | 3 days ago 46% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 79% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 88% | N/A | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 79% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 83% | 2 days ago 63% |
| Advances ODDS (%) | 2 days ago 84% | 2 days ago 75% | 2 days ago 61% |
| Declines ODDS (%) | 6 days ago 89% | 5 days ago 87% | 11 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 82% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 82% | 2 days ago 64% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| JETIX | 17.16 | N/A | N/A |
| abrdn Focused Em Markets ex-China Instl | |||
| JDEZX | 15.29 | N/A | N/A |
| PGIM Jennison Global Equity Income Z | |||
| NWHLX | 11.35 | N/A | N/A |
| Nationwide Bailard Intl Eqs M | |||
| HILYX | 24.32 | N/A | N/A |
| Hartford International Value Y | |||
| APDRX | 34.92 | -0.06 | -0.17% |
| Artisan Global Opportunities Advisor | |||
PRTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with RCKT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then RCKT could also see price increases.
| Ticker / NAME | Correlation To PRTA | 1D Price Change % | ||
|---|---|---|---|---|
| PRTA | 100% | +2.36% | ||
| RCKT - PRTA | 52% Loosely correlated | +0.66% | ||
| SVRA - PRTA | 46% Loosely correlated | +1.00% | ||
| DNLI - PRTA | 40% Loosely correlated | +1.66% | ||
| AXON - PRTA | 38% Loosely correlated | +0.59% | ||
| OCUL - PRTA | 37% Loosely correlated | -0.24% | ||
More | ||||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ROIV. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +2.55% | ||
| ROIV - REGN | 42% Loosely correlated | +0.85% | ||
| IDYA - REGN | 40% Loosely correlated | -0.16% | ||
| TECH - REGN | 40% Loosely correlated | -0.26% | ||
| ACLX - REGN | 39% Loosely correlated | +3.09% | ||
| SMMT - REGN | 38% Loosely correlated | +0.91% | ||
More | ||||